Since the Protecting Access to Medicare Act of 2014 (PAMA), clinical laboratories have been tasked to do more with less due to an increase in finical pressure. Over the next 3 years, clinical laboratories will face Medicare cuts of up to 30% due to the Centers for Medicare and Medicaid Services’ (CMS) new fee schedule. With the continuous decline in reimbursements, it is necessary for clinical laboratories to implement cost-reduction strategies, assuring their success. With over 35 years of experience, MedTest Dx partners with clinical laboratories by maximizing their efficiencies through our state-of-the-art diagnostic analyzers and reagents. This has allowed many of our customers to stay competitive in this dynamic market.